Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Prostatic Neoplasms 6Neoplasms by Histologic Type 2Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lymphatic Diseases 2Immune System Diseases 2Gastro-enteropancreatic neuroendocrine tumor 2AIDS-Related Complex 2Urogenital Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Recurrence 1Prostatic Diseases 1Prostate Cancer Metastatic 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1

Interventions

Lutetium-177 1Lutetium 1Ga(III)-DOTATOC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Gastroenteropancreatic Neuroendocrine Tumor × Lutetium × Clear all
NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
220 enrolled
EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡